Predictive value of serum HBcrAg in antiviral therapy for chronic hepatitis B
Shiyu Wang, Hongxiao Hao, Wen Deng, Lu Zhang, Weihua Cao, Ziyu Zhang, Xinxin Li, Yaqin Zhang, Xin Wei, Linmei Yao, Zixuan Gao, Shuojie Wang, Minghui Li · 2026
Read Predictive value of serum HBcrAg in antiviral therapy for chronic hepatitis B by Shiyu Wang, Hongxiao Hao, Wen Deng, Lu Zhang, Weihua Cao, Ziyu Zhang, Xinxin Li, Yaqin Zhang, Xin Wei, Linmei Yao, Zixuan Gao, Shuojie Wang, Minghui Li (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13582454.txt.
Description
Shiyu Wang and a large team of co-authors review a blood marker called HBcrAg and its use in treating long-term hepatitis B, in a paper published in twenty twenty-six. Care for this liver disease is shifting from endless virus control toward safe stopping of drugs and, one day, a full cure. Older blood tests track the virus poorly once treatment has run for years.
The marker reflects how active the virus's hidden store inside liver cells still is. The review sums up what is known about its biology and its power to predict outcomes. It may help pick which patients suit add-on immune therapy and who can stop drugs safely. The authors also note gaps that still limit its use in clinics.
Catalog record
| CREATOR | Shiyu Wang, Hongxiao Hao, Wen Deng, Lu Zhang, Weihua Cao, Ziyu Zhang, Xinxin Li, Yaqin Zhang, Xin Wei, Linmei Yao, Zixuan Gao, Shuojie Wang, Minghui Li |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 51 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |